La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Jianmin Pharmaceutical GroupLtd Résultats passés
Passé contrôle des critères 4/6
Jianmin Pharmaceutical GroupLtd has been growing earnings at an average annual rate of 35.6%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 14.6% per year. Jianmin Pharmaceutical GroupLtd's return on equity is 22%, and it has net margins of 12.5%.
Informations clés
35.6%
Taux de croissance des bénéfices
35.6%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 14.6% |
| Rendement des fonds propres | 22.0% |
| Marge nette | 12.5% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
The Market Doesn't Like What It Sees From Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Earnings Yet As Shares Tumble 27%
Jul 12
We Think Jianmin Pharmaceutical GroupLtd (SHSE:600976) Can Stay On Top Of Its Debt
Jun 30We Ran A Stock Scan For Earnings Growth And Jianmin Pharmaceutical GroupLtd (SHSE:600976) Passed With Ease
May 21We Think That There Are Issues Underlying Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Earnings
Apr 26Ventilation des recettes et des dépenses
Comment Jianmin Pharmaceutical GroupLtd gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 4,061 | 508 | 1,448 | 79 |
| 31 Mar 24 | 4,170 | 521 | 1,441 | 79 |
| 31 Dec 23 | 4,213 | 521 | 1,518 | 74 |
| 30 Sep 23 | 3,948 | 508 | 1,425 | 78 |
| 30 Jun 23 | 3,965 | 472 | 1,409 | 78 |
| 31 Mar 23 | 3,736 | 419 | 1,311 | 74 |
| 31 Dec 22 | 3,641 | 408 | 1,214 | 73 |
| 30 Sep 22 | 3,503 | 363 | 1,192 | 74 |
| 30 Jun 22 | 3,344 | 326 | 1,126 | 67 |
| 31 Mar 22 | 3,376 | 324 | 1,125 | 62 |
| 31 Dec 21 | 3,299 | 305 | 1,134 | 53 |
| 30 Sep 21 | 3,456 | 279 | 1,135 | 39 |
| 30 Jun 21 | 3,221 | 258 | 1,083 | 38 |
| 31 Mar 21 | 2,857 | 199 | 1,056 | 41 |
| 01 Jan 21 | 2,456 | 148 | 891 | 37 |
| 30 Sep 20 | 2,013 | 144 | 812 | 45 |
| 30 Jun 20 | 2,154 | 93 | 801 | 42 |
| 31 Mar 20 | 2,164 | 83 | 780 | 36 |
| 01 Jan 20 | 2,239 | 91 | 791 | 41 |
| 30 Sep 19 | 2,402 | 82 | 745 | 28 |
| 30 Jun 19 | 2,199 | 80 | 696 | 30 |
| 31 Mar 19 | 2,183 | 79 | 668 | 29 |
| 01 Jan 19 | 2,161 | 81 | 671 | 26 |
| 30 Sep 18 | 2,188 | 91 | 740 | 27 |
| 30 Jun 18 | 2,311 | 100 | 721 | 35 |
| 31 Mar 18 | 2,625 | 102 | 683 | 30 |
| 31 Dec 17 | 2,712 | 91 | 647 | 24 |
| 30 Sep 17 | 2,748 | 81 | 604 | 15 |
| 30 Jun 17 | 2,677 | 71 | 579 | 0 |
| 31 Mar 17 | 2,315 | 59 | 543 | 0 |
| 31 Dec 16 | 2,364 | 65 | 509 | 0 |
| 30 Sep 16 | 2,495 | 69 | 456 | 0 |
| 30 Jun 16 | 2,430 | 80 | 448 | 0 |
| 31 Mar 16 | 2,449 | 83 | 424 | 0 |
| 31 Dec 15 | 2,281 | 86 | 404 | 0 |
| 30 Sep 15 | 1,953 | 86 | 384 | 0 |
| 30 Jun 15 | 1,860 | 102 | 324 | 0 |
| 31 Mar 15 | 1,748 | 114 | 317 | 0 |
| 31 Dec 14 | 1,753 | 116 | 328 | 0 |
| 30 Sep 14 | 1,685 | 118 | 314 | 0 |
| 30 Jun 14 | 1,716 | 108 | 332 | 0 |
| 31 Mar 14 | 1,867 | 98 | 339 | 0 |
| 31 Dec 13 | 1,992 | 96 | 336 | 0 |
| 30 Sep 13 | 1,945 | 99 | 324 | 0 |
Des revenus de qualité: 600976 has a high level of non-cash earnings.
Augmentation de la marge bénéficiaire: 600976's current net profit margins (12.5%) are higher than last year (11.9%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 600976's earnings have grown significantly by 35.6% per year over the past 5 years.
Accélération de la croissance: 600976's earnings growth over the past year (7.7%) is below its 5-year average (35.6% per year).
Bénéfices par rapport au secteur d'activité: 600976 earnings growth over the past year (7.7%) exceeded the Pharmaceuticals industry -0.8%.
Rendement des fonds propres
ROE élevé: 600976's Return on Equity (22%) is considered high.